ACT is a personalized immunotherapy that is based on the intravenous re-administration of autologous, ex vivo-expanded T cells (retrieved either from the tumor tissue or peripheral blood) in combination with a high dose of Interleukin-2 (IL-2) and preceded by a non-myeloablative lymphodepleting chemotherapy regimen [18,20,21,22]. The gene discussed is IL2; the disease is neoplasm.